ATAGI update following weekly COVID-19 meeting – 18 May 2022

An update from the Australian Technical Advisory Group on Immunisation (ATAGI) following their weekly meeting on 18 May 2022.

Date published:
General public

Latest recommendation updates

ATAGI have not published any updated advice or recommendations since 29 April 2022.

Recent ATAGI considerations

On Wednesday 18 May 2022, ATAGI met to consider the latest developments relating to COVID-19 immunisation. As of 17 May 2022, over 58 million doses of COVID-19 vaccines have been administered in Australia.

ATAGI note the increasing number of influenza notifications occurring nationally and continue to encourage all eligible groups to receive an influenza vaccine as soon as possible.

Following a review of evidence relating to need for 4th (winter) doses of COVID-19 vaccine for at risk groups, ATAGI are finalising advice for expanded groups recommended to receive a 4th dose to protect against severe disease.

ATAGI continue to emphasise the importance of remaining up to date with COVID-19 vaccinations by receiving the primary course and a booster dose, with three doses providing protection against severe disease, hospitalisation and death for healthy people.

Ongoing review of adverse events and safety information

The TGA Weekly Report provides a detailed breakdown of adverse events following immunisation, including Australian rates of myocarditis and pericarditis.

Resources and recent statements

More information can be found in the following resources:

More information can be found on the Department of Health website, with resources for both providers and patients.

Help us improve

If you would like a response please use the enquiries form instead.